We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon.
- Authors
Lell, Bertrand; Agnandji, Selidji; von Glasenapp, Isabelle; Haertle, Sonja; Oyakhiromen, Sunny; Issifou, Saadou; Vekemans, Johan; Leach, Amanda; Lievens, Marc; Dubois, Marie-Claude; Demoitie, Marie-Ange; Carter, Terrell; Villafana, Tonya; Ballou, W. Ripley; Cohen, Joe; Kremsner, Peter G.
- Abstract
Background: The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporozoite protein fused to the Hepatitis B surface antigen. Two Adjuvant Systems are in development for this vaccine, an oil-in water emulsion - based formulation (AS02) and a formulation based on liposomes (AS01). Methods & Principal Findings: In this Phase II, double-blind study (NCT00307021), 180 healthy Gabonese children aged 18 months to 4 years were randomized to receive either RTS,S/AS01E or RTS,S/AS02D, on a 0-1-2 month vaccination schedule. The children were followed-up daily for six days after each vaccination and monthly for 14 months. Blood samples were collected at 4 time-points. Both vaccines were well tolerated. Safety parameters were distributed similarly between the two groups. Both vaccines elicited a strong specific immune response after Doses 2 and 3 with a ratio of anti-CS GMT titers (AS02D/AS01E) of 0.88 (95% CI: 0.68-1.15) post-Dose 3. After Doses 2 and 3 of experimental vaccines, anti-CS and anti-HBs antibody GMTs were higher in children who had been previously vaccinated with at least one dose of hepatitis B vaccine compared to those not previously vaccinated. Conclusions: RTS,S/AS01E proved similarly as well tolerated and immunogenic as RTS,S/AS02D, completing an essential step in the age de-escalation process within the RTS,S clinical development plan. Trial Registration: ClinicalTrials.gov. NCT00307021
- Subjects
GABON; MALARIA vaccines; ANTIGENS; PROTEINS; HEPATITIS B; CELL surface antigens; IMMUNE response; DRUG dosage; CLINICAL trials
- Publication
PLoS ONE, 2009, Vol 4, Issue 10, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0007611